Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M443Revenue (TTM) $M319Net Margin (%)24.5Altman Z-Score2.8
Enterprise Value $M167EPS (TTM) $0.5Operating Margin %49.1Piotroski F-Score5
P/E(ttm)5.6Beneish M-Score-2.6Pre-tax Margin (%)43.6Higher ROA y-yN
Price/Book0.510-y EBITDA Growth Rate %2.1Quick Ratio3.1Cash flow > EarningsN
Price/Sales1.55-y EBITDA Growth Rate %-8.2Current Ratio3.2Lower Leverage y-yY
Price/Free Cash Flow6.4y-y EBITDA Growth Rate %-38.4ROA % (ttm)6.3Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)10.0Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M154ROIC % (ttm)13.7Gross Margin Increase y-yN

Gurus Latest Trades with PDLI

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

PDLI is held by these investors:



PDLI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GARCIA PETER SVice President, CFO 2017-03-24Buy25,000$1.9845.45view
GARCIA PETER SVice President, CFO 2016-08-09Buy10,000$3-4view
GARCIA PETER SVice President, CFO 2015-12-15Buy15,000$3.5-17.71view
Pietzke SteffenController and CAO 2015-12-07Buy20,590$3.64-20.88view
GARCIA PETER SVice President, CFO 2015-08-14Buy20,000$5.83-50.6view
SELICK HAROLD EDirector 2014-11-26Buy6,000$8.08-64.36view
Lindell Jody SDirector 2011-03-15Buy374$5.33-45.97view
LARSON CHRISTINE RVice President and CFO 2010-05-14Buy5,000$5.71-49.56view
LARSON CHRISTINE RVice President and CFO 2010-04-30Buy10,000$6.18-53.4view
KLEIN JOSEPH IIIDirector 2009-11-04Sell24,000$8.33-65.43view

Press Releases about PDLI :

Quarterly/Annual Reports about PDLI:

News about PDLI:

Articles On GuruFocus.com
9 Positions Charles Brandes Increased in the Past 2 Quarters Nov 15 2017 
Noden Pharma Announces FDA Approval of Tekturna®(aliskiren) Oral Pellets for the Treatment of Hyper Nov 15 2017 
Factors of Influence in 2018, Key Indicators and Opportunity within Tegna, Inpixon, Honeywell Intern Nov 09 2017 
PDL BioPharma's Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide Updat Nov 08 2017 
PDL BioPharma to Present at Two Upcoming Investor Conferences Nov 07 2017 
PDL BioPharma Issues Statement in Response to Neos Therapeutics Rejection of PDL Acquisition Proposa Oct 30 2017 
Neos Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from PDL BioPharma Oct 30 2017 
PDL BioPharma Announces Settlement Agreement with Valeant Oct 30 2017 
Neos Therapeutics to Review Unsolicited Proposal from PDL BioPharma Oct 26 2017 
PDL BioPharma Proposes to Acquire Neos Therapeutics for $10.25 per Share in Cash Oct 26 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK